<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118010</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00114230</org_study_id>
    <nct_id>NCT04118010</nct_id>
  </id_info>
  <brief_title>Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis</brief_title>
  <official_title>Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess if administration of high-dose vitamin D and a commonly used prebiotic
      (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal
      functions in Cystic Fibrosis with the additive or synergistic effects of the combination of
      vitamin D + inulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic fibrosis (CF) is the most common life-shortening genetic condition among Caucasians in
      the United States. Individuals with CF have an altered gastrointestinal (GI) microbiota,
      which may be a result of chronic systemic inflammation and infection, frequent use of
      antibiotics, and/or medically prescribed and habitual high-fat/high-calorie diets.

      The study will assess if administration of high-dose vitamin D and a commonly used prebiotic
      (inulin) is effective to reduce gastrointestinal dysbiosis and to improve critical intestinal
      functions in Cystic Fibrosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in GI microbiota composition</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Changes in GI microbiota composition will be determined using 16S rRNA gene sequencing and microbiome-dependent metabolites pathways in stool and plasma using high-resolution metabolomics analysis.Changes in GI microbiota composition will be reported as a percentage of bacteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GI microbiota diversity</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Changes in GI microbiota diversity will be determined using 16S rRNA gene sequencing and microbiome-dependent metabolites pathways in stool and plasma using high-resolution metabolomics analysis.Changes in GI microbiota diversity will be reported as the Shannon Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in GI microbiota richness</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Changes in GI microbiota richness will be determined using 16S rRNA gene sequencing and microbiome-dependent metabolites pathways in stool and plasma using high-resolution metabolomics analysis.Changes in GI microbiota richness will be reported as a number of populations of microorganisms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calprotectin level in the stool</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Calprotectin is a protein released by a type of white blood cell called a neutrophil. When there is inflammation in the gastrointestinal (GI) tract, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipocalin-2 blood level</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Lipocalin-2 (LCN2), also known as oncogene 24p3 or neutrophil gelatinase-associated lipocalin (NGAL), is a protein that in humans is encoded by the LCN2 gene.NGAL is involved in innate immunity by sequestrating iron that in turn limits bacterial growth.It is expressed in neutrophils and in low levels in the kidney, prostate, and epithelia of the respiratory and alimentary tracts.NGAL is used as a biomarker of kidney injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum C-reactive protein blood level</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>C-reactive protein (CRP) is a substance produced by the liver in response to inflammation. A high level of CRP in the blood is a marker of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor necrosis factor (TNF) blood level</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important roles in diverse cellular events such as cell survival, proliferation, differentiation, and death. As a pro-inflammatory cytokine, TNF is secreted by inflammatory cells, which may be involved in inflammation-associated carcinogenesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin-6 blood level</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin-8 blood level</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>IL-8 is a chemotactic factor that attracts neutrophils, basophils, and T-cells, but not monocytes. It is also involved in neutrophil activation. It is released from several cell types in response to an inflammatory stimulus.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Dysbiosis</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 and Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 50,000 IU/week and 12 g/day chicory-derived prebiotic inulin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 and placebo Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 50,000 IU/week and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vitamin D3 and Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Matching to Vitamin D3 placebo capsules, and 12 g/day chicory-derived prebiotic inulin for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vitamin D3 and placebo Inulin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching to Vitamin D3 placebo capsules, and 12 g/day corn-derived maltodextrin/day as the prebiotic placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>High-dose vitamin D3 50,000 IU /week for 12 weeks</description>
    <arm_group_label>Vitamin D3 and Inulin</arm_group_label>
    <arm_group_label>Vitamin D3 and placebo Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vitamin D3</intervention_name>
    <description>Matching to Vitamin D3 placebo capsules for 12 weeks</description>
    <arm_group_label>Placebo vitamin D3 and Inulin</arm_group_label>
    <arm_group_label>Placebo vitamin D3 and placebo Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Chicory-derived prebiotic inulin 12 g/day for 12 weeks</description>
    <arm_group_label>Placebo vitamin D3 and Inulin</arm_group_label>
    <arm_group_label>Vitamin D3 and Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Inulin</intervention_name>
    <description>Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks</description>
    <arm_group_label>Placebo vitamin D3 and placebo Inulin</arm_group_label>
    <arm_group_label>Vitamin D3 and placebo Inulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male and female patients (age &gt; 18 years) with confirmed CF by genetic mutation and/or
             sweat chloride testing,

          2. stable pulmonary function (no greater than 5% difference in FEV1% predicted from
             previous measurement within the past year),

          3. not currently on oral or systemic antibiotics for pulmonary exacerbation,

          4. vitamin D deficient/insufficient (25(OH)D, 6 - 30 ng/mL) with most recent 25(OH)D in
             the past 12 months,

          5. use of CFTR modulator therapy is allowed

        Exclusion Criteria:

          1. severe vitamin D deficiency 25(OH)D ≤ 5 ng/mL or hypocalcemia or hypercalcemia,

          2. active GI disease, abdominal pain and/or diarrhea,

          3. chronic kidney disease worse than stage 3 (eGFR &lt; ml/min per 1.73 m2),

          4. any vitamin D supplement use &gt;2,000 IU or vitamin D analogue,

          5. use of immunosuppressants or history of organ transplantation,

          6. current use of probiotics or prebiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vin Tangpricha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vin Tangpricha, MD</last_name>
    <phone>404-727-7254</phone>
    <email>vtangpr@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vin Tangpricha, MD</last_name>
      <phone>404-727-7254</phone>
      <email>vin.tangpricha@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Vin Tangpricha, MD, PH.D</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Gastrointestinal Dysbiosis</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Prebiotic</keyword>
  <keyword>Inulin</keyword>
  <keyword>Gut microbiome</keyword>
  <keyword>Intestinal inflammation</keyword>
  <keyword>Intestinal absorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual de-identified participant data (including data dictionaries) be shared with listed investigators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Projected December 2023</ipd_time_frame>
    <ipd_access_criteria>Protocol and reported primary and secondary outcomes will be be shared on request for statistical analyses with listed investigators</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

